[Neurophysiological studies on the temporary paresis in myotonia congenita and dystrophia myotonica].
D000200:Action Potentials; D000328:Adult; D002462:Cell Membrane; D005260:Female; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction; D009129:Muscle Tonus; D009224:Myotonia Congenita / Q000188:drug therapy / Q000503:physiopathology*; D009223:Myotonic Dystrophy / Q000188:drug therapy / Q000503:physiopathology*; D009388:Neostigmine / Q000627:therapeutic use; D009469:Neuromuscular Junction; D010243:Paralysis; D011342:Procainamide / Q000627:therapeutic use; D013997:Time Factors; D014459:Ulnar Nerve / Q000503:physiopathology
D006146:Guanidines; D009388:Neostigmine; D008274:Magnesium; D011342:Procainamide
Neurophysiologische Untersuchungen über das Stadium passagerer Lähmung bei Myotonia congenita und Dystrophia myotonica.